

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (original) A pharmaceutical composition comprising i) ketotifen or an analog thereof and ii) a chemotherapeutic drug subject to multi-drug resistance by P-gp.
2. (cancelled)
3. (cancelled)
4. (cancelled)
5. (cancelled)
6. (amended) The pharmaceutical composition according to ~~any of the claims 1 to 5~~, wherein the chemotherapeutic drug subject to multi-drug resistance by P-gp comprises an anthracycline.
7. (amended) The pharmaceutical composition according to ~~any of the claims 1 to 5~~, wherein the chemotherapeutic drug subject to multi-drug resistance by P-gp comprises doxorubicin or an analog thereof.
8. (original) A kit comprising the agents i) ketotifen or an analog thereof and ii) a chemotherapeutic drug subject to multi-drug resistance by P-gp, and directions for administering i) and ii) to an animal.
9. (cancelled)
10. (cancelled)
11. (amended) The pharmaceutical composition of ~~claims 1 to 7 or the agents of the kit of claims 8 to 10~~, in an oral, intravenous, intraperitoneal, subcutaneous or rectal dosage form or in combination of the foregoing dosage forms.
12. (cancelled)
13. (cancelled)
14. (cancelled)
15. (cancelled)

16. (cancelled)
17. (cancelled)
18. (cancelled)
19. (cancelled)
20. (amended) A method for i) preventing or treating multi-drug resistance in an animal or ii) preventing a chemotherapeutic drug subject to multi-drug resistance by P-gp induced cardiac tissue damage in an animal, comprising administering to the animal an effective amount of the pharmaceutical composition of claim 14.
21. (original) The method according to claim 20, wherein the chemotherapeutic drug subject to multi-drug resistance by P-gp comprises an anthracycline.
22. (original) The method according to claim 20, wherein the chemotherapeutic drug subject to multi-drug resistance by P-gp comprises doxorubicin or an analog thereof.
23. (amended) A method for preventing or treating multi-drug resistance in cancer cells, tumors or neoplasia, comprising administering to the animal an effective amount of the pharmaceutical composition of claim 15.
24. (original) The method according to claim 23, wherein the chemotherapeutic drug subject to multi-drug resistance by P-gp comprises an anthracycline.
25. (original) The method according to claim 23, wherein the chemotherapeutic drug subject to multi-drug resistance by P-gp comprises doxorubicin or an analog thereof.
26. (original) A method for treating cancer in an animal, comprising  
administering to the animal an effective amount of ketotifen or an analog thereof, and  
administering to the animal an effective amount of a chemotherapeutic drug subject to multi-drug resistance by P-gp.
27. (original) The method according to claim 26, wherein the chemotherapeutic drug subject to multi-drug resistance by P-gp comprises an anthracycline.
28. (original) The method according to claim 26, wherein the chemotherapeutic drug subject to multi-drug resistance by P-gp comprises doxorubicin or an analog thereof.
29. (original) The method of claim 28, wherein the ketotifen is administered prior to the doxorubicin.

30. (original) The method of claim 29, wherein the ketotifen is administered at least 30 minutes prior to the doxorubicin.
31. (amended) The method of ~~any one of claims 12 to 19 and 26 to 30~~ wherein ketotifen or analog thereof and doxorubicin or analog thereof are administered orally, intravenously, intraperitoneally, subcutaneously or rectally or by a combination of more than one of the foregoing.
32. (cancelled)
33. (cancelled)
34. (cancelled)
35. (cancelled)
36. (cancelled)
37. (cancelled)
38. (cancelled)
39. (cancelled)
40. (cancelled)
41. (cancelled)
42. (cancelled)
43. (cancelled)
44. (cancelled)
45. (original) A method of determining whether cancer should be treated with ketotifen or an analog thereof and a chemotherapeutic drug subject to multi-drug resistance by P-gp, comprising determining whether P-gp is overexpressed by the cell.
46. (cancelled)
47. (cancelled)
48. (cancelled)
49. (cancelled)
50. (cancelled)
51. (cancelled)

52. (cancelled)

53. (amended) The method of claims ~~45 to 52~~, further comprising treating the cancer with ketotifen or an analog thereof and a chemotherapeutic drug subject to multi-drug resistance by P-gp.

54. (cancelled)

55. (cancelled)

56. (original) A method for i) preventing or treating multi-drug resistance in an animal or ii) preventing a chemotherapeutic drug subject to multi-drug resistance by P-gp induced cardiac tissue damage in an animal, comprising administering to the animal an effective amount of a compound having MDR-reversing and cardiac-protective activity.

57. (cancelled)

58. (cancelled)